Target intelligence / Profile preview

Mitochondrial fission factor (MFF)

Target
MFF
Molecular classification
Other (Tail-anchored membrane protein), Regulatory protein associated with membrane trafficking
01

Overview

Mitochondrial fission factor (MFF) is a tail-anchored membrane protein localized to the mitochondrial outer membrane and peroxisomes[1][2][4][5]. MFF is essential for the recruitment of dynamin-related protein 1 (Drp1/DNM1L), a GTPase that mediates mitochondrial and peroxisomal fission[4][5]. Loss or suppression of MFF leads to elongated, interconnected mitochondrial networks, while overexpression causes mitochondrial fragmentation[2][4]. Its role is critical for cellular apoptosis, energy homeostasis, and adaptation to stress. Malfunction or dysregulation of MFF has been implicated in cancer, neurodegeneration (such as Huntington’s and Alzheimer’s diseases), cardiovascular, and metabolic disorders. Although not currently a direct drug target, modulation of MFF-related fission pathways represents an area of emerging therapeutic interest[4][5][6].

Other names
MFFC2orf33Mitochondrial fission factorEMPF2AD030AD033GL004MFF protein (for generic references)
02

Mechanism of action

Inhibition or activation of mitochondrial fission via modulation of MFF-Drp1 interaction (potential mechanism for future drugs); Alteration of mitochondrial morphology by influencing recruitment of Drp1 to mitochondria; Modulation of apoptosis pathways through control of cytochrome c release.

03

Biological functions

Mitochondrial fission (division of mitochondria)Peroxisomal fission (division of peroxisomes)Apoptosis regulation (via influencing cytochrome c release)Cell death modulation (downstream effects of fission)Cellular adaptation to stress (through mitochondrial morphology)
04

Disease associations

Neurodegenerative disease (e.g., Huntington’s, Alzheimer’s)Metabolic disorderCardiovascular diseaseCancerOther (potentially involved in rare mitochondrial or peroxisomal disorders)
05

Safety considerations

Therapeutic challenges include potential off-target effects due to disruption of normal mitochondrial and peroxisomal division, impacting cell survival and energy metabolismUnintended inhibition may cause defects in cell growth, apoptosis, and organelle function
06

Interacting drugs

No approved drugs directly target MFF as of the current clinical landscape

2 more in the full profile.

07

Biomarkers

No established clinical biomarkers for MFF patient selection or therapeutic efficacy monitoringPotential future utility in monitoring mitochondrial morphology in disease states

Beyond the preview

Go deeper on Mitochondrial fission factor (MFF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitochondrial fission factor (MFF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call